Disc Medicine

NASDAQ: IRON ↗ $70.79 USD ~$700M MCAP

#Erythropoietic Protoporphyria (EPP)#Rare Blood Disorders #Anemia of Myelofibrosis #Diamond-Blackfan Anemia #Hematology

Disc Medicine is a clinical-stage biopharmaceutical company developing novel hematology therapeutics for patients with serious and rare blood diseases. The company's pipeline includes bitopertin (a glycine transport-1 inhibitor) for erythropoietic protoporphyria (EPP) and other hematologic disorders.

Company Info

Sector: Biotechnology / Rare Hematology

Headquarters: Watertown, Massachusetts, USA

Founded: 2017

Website: www.discmedicine.com/

Upcoming Milestones & Key Dates

Q4 2026 / Q1 2027

Clinical Trial

APOLLO Phase 3 top-line data for bitopertin in EPP

Q2 2026

Earnings

Q1 2026 Earnings — Pipeline update and FDA interaction summary

Clinical Development Pipeline

Bitopertin

Target: Glycine transporter 1 (GlyT1) inhibitor

Erythropoietic protoporphyria (EPP)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

DISC-0974

Target: Anti-hemojuvelin monoclonal antibody (hemojuvelin modulator)

Anemia of myelofibrosis and other anemias

Preclinical

Phase 1

Phase 2

Phase 3

Approved

DISC-0974

Target: Anti-hemojuvelin monoclonal antibody

Anemia in patients with chronic kidney disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Disc Medicine's FDA Meeting Sets 'Clear Path' for Embattled Rare Blood Disease Drug ↗

Following productive meetings with the FDA, Disc Medicine outlined a regulatory path forward for its rare blood disease program, with Phase 3 data and a potential approval submission targeted for late 2026 / early 2027.

Leadership Team

John Quisel, J.D., Ph.D.

President and Chief Executive Officer

Dr. Monica Luchi, M.D.

Chief Medical Officer

Jean M. Franchi

Chief Financial Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →